273 related articles for article (PubMed ID: 7693530)
21. Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS.
Maev IV; Kucheryavyy YA; Gubergrits NB; Bonnacker I; Shelest EA; Janssen-van Solingen GP; Domínguez-Muñoz JE
Drugs R D; 2020 Dec; 20(4):369-376. PubMed ID: 33211277
[TBL] [Abstract][Full Text] [Related]
22. [Sense and nonsense in the treatment of exocrine pancreatic insufficiency].
Mössner J
Schweiz Rundsch Med Prax; 1994 Aug; 83(32):873-6. PubMed ID: 8091057
[TBL] [Abstract][Full Text] [Related]
23. Exocrine pancreatic insufficiency-like syndrome in giraffe.
Lechowski R; Pisarski J; Gosławski J; Lenarcik M
J Wildl Dis; 1991 Oct; 27(4):728-30. PubMed ID: 1721936
[TBL] [Abstract][Full Text] [Related]
24. Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.
Dutta SK; Hubbard VS; Appler M
Dig Dis Sci; 1988 Oct; 33(10):1237-44. PubMed ID: 3168696
[TBL] [Abstract][Full Text] [Related]
25. Exocrine pancreatic substitution: facts and controversies.
Worning H
Scand J Gastroenterol Suppl; 1986; 126():49-54. PubMed ID: 3470919
[TBL] [Abstract][Full Text] [Related]
26. Use of pancreatic Schilling test to determine efficiency of pancreatic enzyme delivery in pancreatic insufficiency.
Brugge WR; Goldberg HJ; Burke CA; Depping BJ
Dig Dis Sci; 1988 Oct; 33(10):1226-32. PubMed ID: 3168695
[TBL] [Abstract][Full Text] [Related]
27. No negative feedback regulation between plasma CCK levels and luminal tryptic activities in patients with pancreatic insufficiency.
Nakamura T; Takebe K; Kudoh K; Ishii M; Imamura K; Kikuchi H; Kasai F; Tandoh Y; Yamada N; Arai Y
Int J Pancreatol; 1995 Feb; 17(1):29-35. PubMed ID: 8568332
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations.
Kraisinger M; Hochhaus G; Stecenko A; Bowser E; Hendeles L
J Clin Pharmacol; 1994 Feb; 34(2):158-66. PubMed ID: 8163716
[TBL] [Abstract][Full Text] [Related]
29. [New trends in the treatment of exocrine pancreas deficiency].
Pap A; Marosi E
Orv Hetil; 1992 Nov; 133(45):2885-90. PubMed ID: 1437112
[TBL] [Abstract][Full Text] [Related]
30. Monitoring enzyme replacement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test.
Mundlos S; Kühnelt P; Adler G
Gut; 1990 Nov; 31(11):1324-8. PubMed ID: 2253920
[TBL] [Abstract][Full Text] [Related]
31. Does the pancreas really produce much more lipase than required for fat digestion?
Carrière F; Grandval P; Gregory PC; Renou C; Henniges F; Sander-Struckmeier S; Laugier R
JOP; 2005 May; 6(3):206-15. PubMed ID: 15883471
[TBL] [Abstract][Full Text] [Related]
32. The Role of Sphere Size in the Context of Pancreatin Therapy for Exocrine Pancreatic Insufficiency: A Systematic Review.
Petersen KU; Malfertheiner P; Mössner J
J Gastrointestin Liver Dis; 2021 Mar; 30(1):132-141. PubMed ID: 33548122
[TBL] [Abstract][Full Text] [Related]
33. Theory and practice in the individualization of oral pancreatic enzyme administration for chronic pancreatitis.
Andrén-Sandberg A
Int J Pancreatol; 1989; 5 Suppl():51-62. PubMed ID: 2702251
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic enzyme therapy for pancreatic exocrine insufficiency.
Domínguez-Muñoz JE
Curr Gastroenterol Rep; 2007 Apr; 9(2):116-22. PubMed ID: 17418056
[TBL] [Abstract][Full Text] [Related]
35. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.
Aloulou A; Puccinelli D; Sarles J; Laugier R; Leblond Y; Carrière F
Aliment Pharmacol Ther; 2008 Feb; 27(3):283-92. PubMed ID: 17973644
[TBL] [Abstract][Full Text] [Related]
36. Stability of pancreatic enzyme activities in duodenal juice after pancreatic stimulation by a test meal or exogenous hormones.
Muller DP; Ghale GK
Ann Clin Biochem; 1982 Mar; 19(Pt 2):89-93. PubMed ID: 6176175
[TBL] [Abstract][Full Text] [Related]
37. A highly stable Yarrowia lipolytica lipase formulation for the treatment of pancreatic exocrine insufficiency.
Turki S; Mrabet G; Jabloun Z; Destain J; Thonart P; Kallel H
Biotechnol Appl Biochem; 2010 Dec; 57(4):139-49. PubMed ID: 20958263
[TBL] [Abstract][Full Text] [Related]
38. [The pH dependence of lipase and trypsin activity].
Gerber B; Siegmund E; Dummler W; Gerber S
Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):190-3. PubMed ID: 3234304
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic enzyme pharmacotherapy.
Ferrone M; Raimondo M; Scolapio JS
Pharmacotherapy; 2007 Jun; 27(6):910-20. PubMed ID: 17542772
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency.
Regan PT; Malagelada JR; DiMagno EP; Glanzman SL; Go VL
N Engl J Med; 1977 Oct; 297(16):854-8. PubMed ID: 20572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
